BioMarin Pharmaceutical Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $1.31B | $942.8M | $755.1M | $724.5M | $587.3M | $649.2M | $437.4M | $494.0M |
| Accounts Receivable | $908.2M | $660.5M | $633.7M | $461.3M | $373.4M | $448.4M | $377.4M | $342.6M |
| Inventory | $1.30B | $1.23B | $1.11B | $894.1M | $776.7M | $698.5M | $680.3M | $530.9M |
| Total Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B |
| Property, Plant & Equipment | $952.5M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $948.7M |
| Goodwill | $196.2M | $196.2M | $196.2M | $196.2M | $196.2M | $196.2M | $197.0M | $197.0M |
| Intangible Assets (Excl. Goodwill) | $213.8M | $255.3M | $294.7M | $338.6M | $388.7M | $417.3M | $456.6M | $491.8M |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B |
| Liabilities | ||||||||
| Accounts Payable | $759.0M | $607.0M | $683.1M | $573.0M | $498.3M | $492.5M | $570.6M | $437.3M |
| Total Current Liabilities | $759.0M | $607.0M | $1.18B | $588.9M | $546.5M | $492.5M | $932.5M | $523.2M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $154.2M | $-194.7M | $-621.6M | $-789.2M | $-930.8M | $-861.6M | $-1.72B | $-1.69B |
| Total Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B |